MiMedx Group, Inc. — Third Quarter 2026 Earnings Summary

MiMedx Group reported net sales of $62.3 million for the third quarter of 2026, a 45% decrease from the prior year period, driven by a 71% decline in Wound sales offset by a 9% increase in Surgical sales. The company achieved positive Adjusted EBITDA of $2.1 million and returned to a net loss of $8.7 million after repaying its remaining $17 million term loan balance. During the quarter, a U.S. District Court vacated the FDA's classification of AXIOFILL as a biological product, remanding the matter for further consideration, and the company secured a $25 million patent license agreement with a competitor. Management forecasts full-year 2026 net sales between $250 million and $260 million while continuing to pursue the acquisition of Sanara MedTech.